{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-128491","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.047482+00:00","generated_at":"2026-05-29T03:43:15.579858+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BMS terminates collaboration with Century Therapeutics without cause; effective March 12, 2025","bullets":["BMS notified Century on Dec 12, 2024 of termination of the 2022 Research, Collaboration and License Agreement.","Termination covers all iPSC-derived NK and gamma delta T cell programs for hematologic malignancies.","Century will evaluate opportunities in AML and multiple myeloma under ongoing strategic review of pre-clinical pipeline.","Both parties will cooperate on termination provisions; no financial details of termination disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-128491","json":"https://secwatch.observer/filing/0001104659-24-128491.json","markdown":"https://secwatch.observer/filing/0001104659-24-128491.md","text":"https://secwatch.observer/filing/0001104659-24-128491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/0001104659-24-128491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/tm2431062d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:43:15.579858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}